Chair NSABP
General Surgery
Dr. Norman Wolmark, MD
|
|
Give Review
Norman Wolmark works in the field of General Surgery. He received awards:"Fellow (FRCSC)" and "Fellow (FACS)". Norman Wolmark is also a published doctor. He has 99 paper published. The most recent paper is: Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy. Doctor Norman Wolmark, MD is registered with Medicare and accepts Medicare payments.
Publications
- Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy.
- Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
- Neoadjuvant plus adjuvant bevacizumab in early Breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
- A polygenic risk score for Breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.
- Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced Breast cancer: NSABP Fou...
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 ...
- Comparative Effectiveness of Sphincter-Sparing Surgery Versus Abdominoperineal Resection in Rectal Cancer: Patient-Reported Outcomes in National Surgical Adjuvant Brea...
- Chemotherapy for isolated locoregional recurrence of Breast cancer (CALOR): a randomised trial.
- Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31.
- Preliminary results of centralized HER2 testing in ductal Carcinoma in situ (DCIS): NSABP B-43.
- Lapatinib as a component of neoadjuvant therapy for HER2-positive operable Breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
- Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive Breast cancer: an NSABP Foundation Resear...
- Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08.
- Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention.
- Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial.
- National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: Advancing the science of recruitment and Breast cancer risk assessment in ...
- Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value.
- Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant Breast and bowel project B-18 and B-...
- Baseline Mammographic Breast Density and the Risk of Invasive Breast Cancer in Postmenopausal Women Participating in the NSABP Study of Tamoxifen and Raloxifene (STAR).
- Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP ...
- Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon Cancer: results from National Surgical Adjuvant Breas...
- Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon Cancer and an intact asy...
- Relationship Between Arm Morbidity and Patient-Reported Outcomes Following Surgery in Women with Node-Negative Breast Cancer: NSABP Protocol B-32.
- Oral clodronate for adjuvant treatment of operable Breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled...
- Evaluation of visual recognition memory for the early diagnosis of Alzheimer's Disease in patients over 75 years.
- Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
- Adjuvant tamoxifen reduces subsequent Breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
- Body mass index and the risk for developing invasive Breast cancer among high-risk women in NSABP P-1 and STAR Breast cancer prevention trials.
- Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's Disease.
- Bevacizumab added to neoadjuvant chemotherapy for Breast cancer.
- Gynecologic conditions in participants in the NSABP Breast cancer prevention study of tamoxifen and raloxifene (STAR).
- Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor-Positive Breast Cancer: Recurrence Score Alone and Integrated With Patho...
- Effect of radiotherapy after Breast-conserving surgery on 10-year recurrence and 15-year Breast cancer death: meta-analysis of individual patient data for 10,801 wom...
- Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for Breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
- Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor-Positive Breast Cancer.
- Fruit and vegetable intake and cognitive function in the SU.VI.MAX 2 prospective study.
- Outcomes among black patients with stage II and III colon Cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
- Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses.
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From...
- Relevance of Breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
- Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2(-) Locally ...
- Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive Breast cancer: resu...
- Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon Cancer trials with fluoropyrimidines with or without oxaliplatin or ir...
- Menstrual history and quality-of-life outcomes in women with node-positive Breast cancer treated with adjuvant therapy on the NSABP B-30 trial.
- Long-term outcomes of invasive ipsilateral Breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
- Thirteen-year prospective study between fish consumption, long-chain n-3 fatty acids intakes and cognitive function.
- Effect of occult metastases on survival in node-negative Breast cancer.
- Phase III trial assessing bevacizumab in stages II and III Carcinoma of the colon: results of NSABP protocol C-08.
- Adherence to nutritional recommendations and subsequent cognitive performance: findings from the prospective Supplementation with Antioxidant Vitamins and Minerals 2 (...
- Amenorrhea from Breast cancer therapy--not a matter of dose.
- Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
- Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the Breast.
- Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with Breast cancer: overall survival findi...
- Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon Cancer treated with surgery alone or surgery ...
- Patient-reported outcomes in sentinel node-negative adjuvant Breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant B...
- Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection.
- [Clinical and EEG approach to the diagnosis of epilepsy in a population of old people with delusion].
- Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive Breast cancer.
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast cancer.
- Longer therapy, iatrogenic amenorrhea, and survival in early Breast cancer.
- Conditional survival and the choice of conditioning set for patients with colon Cancer: an analysis of NSABP trials C-03 through C-07.
- Response to "Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-Breast irrad...
- Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive Breast cancer: results from NSA...
- Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon Cancer: pooled analysis of NSABP C-01 t...
- A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced Breast cancer.
- Association between Disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon c...
- [Audit of eeg'requests in geriatric hospital during 16 months].
- Preoperative multimodality therapy improves disease-free survival in patients with Carcinoma of the rectum: NSABP R-03.
- Surgeon training, protocol compliance, and technical outcomes from Breast cancer sentinel lymph node randomized trial.
- Role of anthracyclines in the treatment of early Breast cancer.
- Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.
- Cancer survivorship research: the challenge of recruiting adult long term Cancer survivors from a cooperative clinical trials group.
- Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II ...
- Prognosis after ipsilateral Breast tumor recurrence and locoregional recurrences in patients treated by Breast-conserving therapy in five National Surgical Adjuvant Br...
- Adjuvant chemotherapy in older women with early-stage Breast cancer.
- The use of tamoxifen and raloxifene for the prevention of Breast cancer.
- Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of Breast...
- The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.
- Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.
- A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced Breast cancer.
- Is sentinel node biopsy necessary in conservatively treated DCIS?
- An association between postoperative radiotherapy for primary Breast cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) studies and the subsequen...
- Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon Cancer: NSABP C-07.
- Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon Cancer: results from NSABP C-07.
- Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Proj...
- Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Proje...
- NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consistin...
- Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon Cancer.
- [Cholinesterase inhibitor therapy in long term care settings].
- Low locoregional recurrence rate among node-negative Breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy...
- Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive Breast cancer.
- Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant Breast and bowel project Breast cancer preve...
- Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for Breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (...
- Effects of tamoxifen vs raloxifene on the risk of developing invasive Breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 ...
- Prognosis after ipsilateral Breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant bre...
- Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III Carcinoma of the colon: results from National Surgica...
- Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable Breast cancer:National Surgical Adjuvant Breast...
- Endogenous sex hormones, Breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Schools
McGill University Faculty of Medicine
McGill University Hospital
University Pittsburgh Hospital
Sloan Kettering Meml Center
Procedures Preformed
- Biopsy of Breast
- Lymph Node Biopsy or Excision
Conditions Treated
- Breast Cancer
- Breast Lump
- Carcinoma in Situ
- Peripheral Vascular Disease (PAD, PVD)
- View All
Doctors Specialties
- General Surgery
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Assurant Health
- Blue Card PPO
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health America PPO
- First Health (Coventry Health Care) PPO
- Geisinger Health Plan
- Golden Rule
- Community Blue PPO
- Choice Care PPO
- Medicaid
- Medical Mutual of Ohio
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Principal Life
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- UPMC Health Plan
Awards
- Fellow (FRCSC)
- Fellow (FACS)
Education
-
Memorial Sloan-Kettering Cancer Center -
University of Pittsburgh Medical Center -
McGill University Faculty of Medicine
Drug Facts
| NPI NUMBER | 1528060357 | |
| NPPES Provider LastName | WOLMARK | |
| NPPES Provider FirstName | NORMAN | |
| NPPES Provider ZIPCode | 152124756 | |
| NPPES Provider State | PA | |
| Specialty Description | Surgical Oncology | |
| Total Claim Count | 193.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1528060357 |
| Last Name Of The Provider | WOLMARK |
| First Name Of The Provider | NORMAN |
| View All |
Similar Doctors
|
|
Dr. Ved P. Kaushik, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David A. Blumberg, MD |
|
|
Dr. Allan Tsung, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John H. Goodworth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles F. Haeussner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wolfgang Schraut, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Wendell E. Zehel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald W. Moorman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alan D. Murdock, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katherine M. Theisen, MD |